EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, CASI: Casi Pharmaceuticals Inc

11 Nov 25 15:59
LAST:

1.380

CHANGE:
 0.04		OPEN:
1.340		HIGH:
1.450		ASK:
1.830		VOLUME:
20.7K
CHG(%):
2.99		PREV:
1.340		LOW:
1.310		BID:
1.340		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
11 Nov 251.3401.4501.3101.38025.0K
10 Nov 251.4001.4101.3001.34026.6K
07 Nov 251.3501.4511.2801.38033.4K
06 Nov 251.3801.4701.3001.33011.5K
05 Nov 251.3101.3701.3101.35021.0K
04 Nov 251.4001.4001.3001.33020.0K
03 Nov 251.4601.4601.3701.39018.0K
31 Oct 251.4401.4401.3701.44019.2K
30 Oct 251.5201.5441.3451.36064.6K
29 Oct 251.6201.7001.4101.42056.7K

COMPANY PROFILE

Name:Casi Pharmaceuticals Inc
About:CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company's hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investigative product; BI-1206, an novel anti-Fc"RIIB antibody for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. It has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.
Sector:Healthcare
Industry:Biotechnology
Address:1701-1702, China Central Office Tower 1, Beijing, China, 100025
Website:https://www.casipharmaceuticals.com
CUSIP:29382F103
CIK:0000895051
ISIN:US14757U1097
FIGI:BBG01DSTT3T7
LEI:549300RYDG4U21PJZ263

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:1.361.8%
MA10:1.370.6%
MA20:1.5310.9%
MA50:1.7627.7%
MA100:1.7124.0%
MA200:1.8937.2%
STO9:23.39
STO14:8.93 
RSI14:29.73 
WPR14:-83.87 
MTM14:-0.23
ROC14:-0.14 
ATR:0.15 
Week High:1.476.5%
Week Low:1.287.8%
Month High:1.9642.0%
Month Low:1.2837.2%
Year High:5.95331.2%
Year Low:1.0926.5%

RECENT SPLITS

Date Ratio
02 Jun 20221-10
01 Jul 20101-11